SEC Filing Summary: Second Sight Medical Products, Inc.
Business Context and Reporting Period
This Form 8-K was filed on April 7, 2021, by Second Sight Medical Products, Inc. (trading symbol: EYES). The filing addresses a regulatory compliance matter with The Nasdaq Stock Market regarding the composition of the company's audit committee. Note: The request metadata references "Vivani Medical, Inc.," but the filing text explicitly identifies the registrant as Second Sight Medical Products, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance.
Material Changes
The material change reported is the resolution of a Nasdaq delisting threat. The company previously received notice on July 15, 2020 (text contains a date discrepancy stating July 15, 2021, which is logically prior to the April 2021 filing; context implies a prior year notice) of non-compliance with Listing Rule 5605(c)(2) regarding audit committee independence. After failing to regain compliance by the March 27, 2021 deadline, Nasdaq initiated delisting procedures. The company successfully appealed this determination following the appointment of Dr. Dean Baker to the board and audit committee.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of compliance. The primary risk addressed was the potential delisting of the company's securities from The Nasdaq Capital Market. This risk has been mitigated, and Nasdaq has determined the matter is closed. No financial guidance or outlook is provided in this filing.
Key Facts for Investor Verification
- The company has regained compliance with Nasdaq Listing Rule 5605(c)(2) regarding audit committee composition.
- Dr. Dean Baker was appointed to the board of directors and audit committee to satisfy the independence requirement.
- Nasdaq has officially closed the delisting proceedings initiated on April 5, 2021.
- The filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.